NCCN HCT Guidelines v2.2026 (April 3, 2026)
Mechanism & Purpose
- High-dose chemotherapy (HDC) destroys residual malignancy → patient’s own stem cells ‘rescue’ hematopoiesis
- NO graft-versus-tumor (GvT) effect — purely cytotoxic benefit
- No GVHD risk, no long-term immunosuppression required
- Lower NRM vs. allo-HCT but HIGHER relapse risk
Indication
| Disease | Auto-HCT Role | Notes |
|---|---|---|
| Multiple Myeloma | Standard of care in eligible patients (consolidation) | Often followed by maintenance lenalidomide |
| Relapsed/Refractory HL | Salvage consolidation after 2nd-line chemo | BEAM/BEAC/TEAM conditioning |
| R/R NHL (DLBCL, MCL, FL) | Salvage consolidation in chemosensitive disease | BEAM/BEAC preferred regimens |
| Testicular Germ Cell Tumors | Relapsed/refractory disease | TI-CE / Carboplatin+Etoposide regimens |
| PCNSL / CNS Lymphoma | Consolidation after induction therapy | Thiotepa + busulfan + Cy conditioning |
| AML (selected patients) | Consolidation in CR1/CR2 (no allo-HCT donor) | Busulfan-based conditioning |
Stem Cell Mobilization (NCCN HCT-4/HCT-4A)
Minimum CD34+ Preferred Yield: ≥2 × 10⁶ CD34+ cells/kg,
Optimal CD34+ Yield: 4–5 × 10⁶ CD34+ cells/kg.
Yields <2 × 10⁶ CD34+/kg may have a risk of delayed engraftment. Higher yields may result in faster platelet AND neutrophil recovery.
Hematopoietic Cell Mobilization Regimens (NCCN HCT-4A)
- Filgrastim ± Plerixafor
- Filgrastim SC 10 mcg/kg (ABW) daily for 4-5 days and until collection goal is met
- Plerixafor SC 0.24 mg/kg (ABW) (max. 40 mg/day) 11 hours prior to apheresis.
- Most common approach. Plerixafor added upfront or ‘just-in-time’ for poor mobilizers.
- Filgrastim + Cyclophosphamide ± Plerixafor
- Cyclophosphamide IV 1500-3000 mg/m². Apheresis ≥4-5 days after cyclophosphamide.
- Filgrastim SC 10 mcg/kg (ABW) daily for 4-5 days and until the collection goal is met. Start 24h after cyclophosphamide.
- Plerixafor SC 0.24 mg/kg (ABW) (max. 40 mg/day) 11 hours prior to apheresis.
- Higher CD34+ yields vs. G-CSF alone. May reduce tumor burden. Requires monitoring WBC for apheresis timing. Consider institutional CD34+ count-based triggering.
- Sargramostim + Cyclophosphamide ± Plerixafor
- Cyclophosphamide IV 1500-3000 mg/m². Apheresis ≥4-5 days after cyclophosphamide.
- Sargramostim SC 250 mg/m² daily (or IV over 24 h) and until the collection goal is met. Start 24h after cyclophosphamide.
- Plerixafor SC 0.24 mg/kg (ABW) (max. 40 mg/day) 11 hours prior to apheresis.
- Similar efficacy to G-CSF + Cy. Alternative if G-CSF shortage.
- Pegfilgrastim + Plerixafor
- Pegfilgrastim SC 6 mg on Day 1
- Plerixafor SC 0.24 mg/kg (ABW) (max. 40 mg/day) on Day 3 and 11 hours prior to apheresis.
- Convenient single-dose G-CSF. Limited but favorable data. No daily injections. Not preferred as first-line due to limited high-quality evidence.
- Filgrastim + Motixafortide (ONLY in Multiple Myeloma; STORM trial)
- Filgrastim 10 mcg/kg SC daily for 4 days prior to Motixafortide
- Motixafortide SC 1.25 mg/kg (ABW) 10-14h prior apheresis
- NEW cyclic peptide CXCR4 inhibitor. Phase III: 92.5% of MM pts achieved ≥6×10⁶ CD34/kg in ≤2 apheresis days vs. 26.2% with G-CSF alone. Approved for MM.
Motixafortide: NEW cyclic peptide CXCR4 inhibitor. STORM trial, Phase III: 92.5% of MM pts achieved ≥6×10⁶ CD34/kg in ≤2 apheresis days vs. 26.2% with G-CSF alone. Approved for MM.Motixafortide
Risk Factors for Poor Mobilization
| Patient Factors | Treatment Factors |
|---|---|
| Older age | Prior fludarabine (lymphotoxic, depletes stem cells) |
| Extensive prior chemotherapy (>4 lines) | Prior lenalidomide therapy (especially ≥4 cycles) |
| Low baseline WBC (<4000/μL) | Prior radiation to marrow-containing regions |
| Bone marrow involvement at collection time | High cumulative alkylating agent exposure |
Rescue Strategies (NCCN HCT-4)
- Increase G-CSF dose or change to twice-daily dosing
- Add plerixafor ‘just-in-time’ to G-CSF (even after 1st apheresis day if <2 × 10⁶ collected). Plerixafor SC 0.24 mg/kg (ABW) (max. 40 mg/day) 11 hours prior to apheresis.
- Switch to chemo-mobilization ± plerixafor
- Bone marrow harvest (refer to NMDP/Be The Match)
- Rest 2–4 weeks (if clinically feasible) before remobilization attempt
PLERIXAFOR DOSING: Plerixafor SC 0.24 mg/kg (ABW) (max. 40 mg/day) 11 hours prior to apheresis. RENAL ADJUSTMENT: For CrCl ≤50 mL/min — reduce dose by 30% to 0.16 mg/kg (max 27 mg). Check renal function BEFORE each dose.
CLINICAL PEARL: WBC MONITORING TRICK: For chemo-mobilization, monitor daily WBC and peripheral blood CD34+ count starting Day 4 post-Cy. Initiate apheresis when WBC rising rapidly (nadir rebound). Many centers trigger by peripheral CD34+ count (target ≥10–20/μL by institutional protocol).
Conditioning Regimen (NCCN HCT-A)
The regimen choice depends on disease and recipient age/comorbidities.
Intensity: MA, NMA, RIC.
Busulfan plasma exposure unit conversion: AUC 5000 uMxmin = 20.5 mgxh/L. 1
Conditioning Regimen Selection Factors
- Patient age (chronological AND physiological/functional)
- ECOG/KPS performance status
- HCT-CI2 and pertinent comorbidities
- Disease type and remission status (including MRD status)
- History of prior HCT (prior auto-HCT → RIC preferred for allo)
- Graft source (UCB, haplo, MSD, MUD) and degree of HLA disparity
| Intensity | Definition / Examples | Clinical Use |
|---|---|---|
| MYELOABLATIVE (MA) | Causes IRREVERSIBLE (or near-irreversible) pancytopenia. HCT support REQUIRED to prevent aplasia-death. TBI ≥5 Gy single dose OR ≥8 Gy fractionated Busulfan >8 mg/kg PO (>6.4 mg/kg IV) or AUC equivalent | Young, fit patients with AML, ALL, CML, MDS seeking maximum anti-tumor effect and lower relapse risk |
| REDUCED INTENSITY (RIC) | Does NOT fulfill MA or NMA criteria. Cytopenias REQUIRE HCT support but alkylator/TBI doses are reduced vs MA. | Bridge between MA and NMA. Most common for older patients, prior allo-HCT, lymphoma, CLL, plasma cell disorders. |
| NON-MYELOABLATIVE (NMA) | Minimal cytopenia. If graft fails, autologous recovery occurs. TBI ≤2 Gy ± purine analog Total lymphoid irradiation + ATG | Older/comorbid patients. Relies heavily on GvL effect. Lymphoma, CLL, plasma cell disorders, 2nd transplant. |
Conditioning Regimen by Disease
| Disease | Regimen(s) | Dose Notes |
|---|---|---|
| NHL (no CNS) / HL | • BEAM: BCNU + Etoposide + AraC + Melphalan • BEAC: BCNU + Etoposide + AraC + Cyclophosphamide • BCNU + Thiotepa • Bu + Cy + Etoposide • TEAM: Thiotepa + Etoposide + AraC + Melphalan • BeEAM (Bendamustine-based) | BEAM is most common. BCNU dose per BSA. Max BCNU 1200 mg/m² single agent, >600 mg/m² pulmonary tox risk in multi-agent. BeEAM: comparable safety to BEAM without carmustine shortages. |
| PCNSL / NHL with CNS | • Thiotepa + Busulfan + Cyclophosphamide • BCNU + Thiotepa | Thiotepa crosses BBB — critical for CNS lymphoma. Thiotepa skin excretion — shower every 6-8h during infusion. |
| Multiple Myeloma / Plasma Cell Leukemia | • Melphalan 100–200 mg/m² • Melphalan 70–140 mg/m² for select patients • Melphalan + Busulfan (high-risk) | Mel200 is standard. Mel100 for: amyloidosis, age >70, high HCT-CI, low KPS, CKD. BuMel for high-risk MM (trial data from Lahuerta et al. Blood 2025). |
| Germ Cell Tumors | • Carboplatin + Etoposide (TI-CE protocol) | Refer to NCCN Testicular Cancer guidelines. AUC-based carboplatin dosing in this setting. |
| Acute Promyelocytic Leukemia | • Busulfan + Melphalan • Cyclophosphamide + TBI • Busulfan + Cyclophosphamide | Auto-HCT for molecular CR2. Arsenic consolidation often precedes auto-HCT in APL. |
Busulfan PK Monitoring (NCCN HCT-A)
- PK monitoring is REQUIRED for oral busulfan and PREFERRED for IV busulfan.
- Underexposure (relapse ↑ + reduced OS), and Overexposure (VOD/SOS ↑ + NRM ↑).
- Click here for Busulfan PK monitoring.
BUSULFAN + SEIZURE PPX: Do NOT use phenytoin as seizure prophylaxis with busulfan. Phenytoin induces CYP enzymes → increases busulfan clearance → underexposure → relapse risk. Use levetiracetam (preferred) or clonazepam/lorazepam.
CLINICAL PEARL: Busulfan dose for OBESE patients: mg/kg dosing → use 25% adjusted body weight (IBW + 0.25 × [TBW – IBW]). BSA dosing → use total body weight. NEVER dose on TBW for mg/kg regimens in obese patients.
Weight-Based Dosing (NCCN HCT-A, Table 7)
| Drug | Dosing Weight (Standard) | Dosing Weight (Obese TBW >120% IBW) |
|---|---|---|
| Busulfan (mg/kg dosing) | 25% Adjusted BW = IBW + 0.25(TBW–IBW) | Same: 25% Adjusted BW |
| Busulfan (BSA dosing) | BSA based on TOTAL body weight | Same |
| Carmustine (BCNU) | BSA based on TOTAL body weight | 25% Adjusted BW (if TBW >120% IBW) |
| Cyclophosphamide (Cy200) | Lesser of TBW or IBW | IBW if TBW >120% IBW |
| Cyclophosphamide (Cy120) | TBW or IBW | 25% Adjusted BW (if TBW >120% IBW) |
| Cytarabine (AraC) | BSA based on TOTAL body weight | Same |
| Etoposide (mg/kg) | 25% Adjusted BW | Same: 25% Adjusted BW |
| Etoposide (BSA) | BSA based on TOTAL body weight | Same |
| Fludarabine | BSA based on TOTAL body weight | Same |
| Melphalan | BSA based on TOTAL body weight | Same |
| Thiotepa | BSA based on TOTAL body weight (if TBW ≤120% IBW) | 40% Adjusted BW: IBW + 0.4(TBW–IBW) |
| Treosulfan | BSA based on TOTAL body weight | Same |
Special Situations & Contraindications in Conditioning Selection
| Clinical Situation | Conditioning Consideration |
|---|---|
| Significant Pulmonary Dysfunction | CAUTION with: HD busulfan, carmustine (BCNU), HD TBI. If DLCO <60% → pulmonary consult. BCNU pulmonary toxicity is >50% at 600 mg/m² in multi-agent regimens. |
| Significant Liver Dysfunction / Cirrhosis | HD busulfan + HD TBI → increased VOD/SOS risk. Cirrhosis with portal HTN = CONTRAINDICATION for allo-HCT. Dual alkylator regimens after inotuzumab/gemtuzumab → very high VOD risk. |
| Prior Inotuzumab or Gemtuzumab | Dual alkylator-based conditioning → VERY HIGH VOD/SOS risk. Defibrotide prophylaxis often used. Avoid if possible. |
| Prior Checkpoint Inhibitor (PD-1/PD-L1) | Increased GVHD risk pre- or post-HCT. Consider minimum 8–12 week washout window before conditioning start. |
| Prior Mogamulizumab | Increased GVHD risk after allo-HCT. 8–12 week washout recommended. |
| Thiotepa Use | Excreted through SKIN. Requires special skin care protocol: shower every 6–8h during and after infusion. Patients and staff education critical. |
| Sirolimus + Tacrolimus (Prophylaxis) with MA | Higher risk of VOD/SOS and thrombotic microangiopathy (TMA) when combined with MA conditioning. Monitor closely. |
| Prior Auto-HCT | RIC/NMA preferred for subsequent allo-HCT. Higher NRM with MA after prior auto-HCT. |
CLINICAL TRIALS
| Trial | Population | Intervention | Comparator | Key Result |
|---|---|---|---|---|
| BMT CTN 1703 (NEJM 2023) | RIC PBSC allo-HCT (MSD/MUD) | PTCy + Tac + MMF | Tac + MTX (standard) | Superior 1-yr GRFS (52.7% vs 34.9%); lower severe aGVHD + cGVHD. Category 1 for RIC. |
| REACH2 (NEJM 2020) | SR-aGVHD grade II–IV (adults ≥18y) | Ruxolitinib 10 mg BID | Investigator’s choice | Day 28 ORR 62% vs 39% (P<0.001). Median OS 11 vs 6.5 mo. FDA approved. |
| REACH3 (NEJM 2021) | SR/SD cGVHD after 1–2 lines (adult/ped ≥12y) | Ruxolitinib 10 mg BID | BAT (investigator’s choice) | ORR wk 24: 50% vs 26% (P<0.001). FFS >19 vs 6 mo. FDA approved. |
| ROCKstar (Blood 2021) | cGVHD after ≥2 prior lines | Belumosudil 200 mg QD or BID | None (single arm) | ORR 76% including lung cGVHD. DOR 54 weeks. FDA approved 2021. |
| AGAVE-201 (Blood 2023) | cGVHD after ≥2 prior lines, ≥40 kg | Axatilimab-csfr 0.3, 1, or 3 mg/kg IV q2–3 weeks | 3-arm Phase II (randomized doses) | ORR 74% at 0.3 mg/kg (best dose). FDA approved Aug 2024. |
| ABA2 (Blood 2024) | MUD and 1-allele MMUD allo-HCT (MAC/RIC) | Abatacept + CNI + MTX | CNI + MTX (placebo) | Significant reduction severe aGVHD in MMUD. FDA approved for aGVHD prophylaxis. |
| MORPHO (NEJM 2024) | FLT3-mutated AML post allo-HCT | Midostaurin 50 mg BID maintenance × 24 cycles | Placebo | Overall no significant OS/RFS benefit but RFS benefit in MRD-negative subgroup. Informative for clinical practice. |
| MC-FludT.14/L (Lancet Haematol 2020) | Older AML/MDS pts for allo-HCT | Treosulfan + Fludarabine | Busulfan + Fludarabine | Non-inferior EFS (43% vs 26%, P=0.05 for non-inferiority). Less neurotoxicity. |
| Omidubicel Phase III (Blood 2021) | UCB transplant recipients with MA conditioning | Omidubicel-onlv (ex vivo expanded UCB) | Standard UCB transplant | Neutrophil recovery 12 vs 22 days (P<0.001). Less bacterial/fungal infections (37% vs 57%, P=0.027). |
| Remestemcel-L Phase III (BBMT 2020) | Pediatric SR-aGVHD (≥2 months) | Remestemcel-L 2×10⁶ cells/kg IV BIW × 4 weeks | Pre-specified historical control (ORR 45%) | ORR 70.4% (P=0.0003). Day 100 survival 86.8% if responded. FDA approved pediatric. |
CRITICAL PHARMACIST WATCHPOINTS & CLINICAL PEARLS SUMMARY
| Category | Critical Action Item |
|---|---|
| Busulfan TDM | PK monitoring REQUIRED for oral Bu; PREFERRED for IV Bu (v1.2026). AUC target 60–100 mg×h/L. Report in mg×h/L not µM×min. Use levetiracetam NOT phenytoin for seizure prophylaxis. |
| Obese Patient Dosing | Busulfan → 25% ABW. Cyclophosphamide → lesser of TBW/IBW (Cy200) or 25% ABW if >120% IBW (Cy120). Thiotepa → 40% ABW if TBW >120% IBW. Etoposide mg/kg → 25% ABW. |
| Plerixafor Dosing | Dose on ACTUAL body weight. Max 40 mg/day. Renal adjustment: CrCl ≤50 → reduce 30% (0.16 mg/kg, max 27 mg). Administer 11h before apheresis. |
| CNI TDM | Tacrolimus trough 5–15 ng/mL (varies by phase/center). Cyclosporine 200–400 ng/mL. Monitor daily in early post-transplant → then adjust frequency. Check troughs BEFORE dosing. Electrolytes (Mg, K) essential. |
| Ibrutinib Drug Interactions | CYP3A4 substrate. Azoles (vori, posa, fluco) → INCREASE ibrutinib exposure. Dose reduce: Vori/Posa → 140 mg/day. Hold with strong CYP3A4 inhibitors if dose <140 mg possible. |
| Azithromycin Safety | NEVER prescribe azithromycin for BOS PROPHYLAXIS in HCT patients. Only for established BOS TREATMENT. Two RCTs show increased leukemia relapse + secondary neoplasms with prophylactic use. |
| Defibrotide VOD | 6.25 mg/kg IV q6h. Dose NOT adjusted for renal/hepatic. HOLD if active bleeding. Avoid concurrent anticoagulants (additive bleed risk). Not ‘deferiprone’ or ‘deferoxamine’ — confirm drug name. |
| PTCy + Cy Conditioning | If Cy used in conditioning AND PTCy planned post-transplant: FLAG total cyclophosphamide dose. Cumulative cardiotoxicity + hemorrhagic cystitis risk. Mesna coverage needed. |
| Thiotepa Skin Care | Thiotepa excreted through skin. Patient must shower every 6–8h during and for 24h after each infusion. Staff PPE during infusion. Educate nurses AND patient/caregivers. |
| Oral Beclomethasone | COMPOUNDED agent only (not commercially available). Adrenal insufficiency risk with prolonged use. Monitor symptoms. Distinguish from inhaled beclomethasone. |
| Sirolimus + TAC + MA | Combination of sirolimus + tacrolimus with MA conditioning → higher VOD/SOS risk + TMA risk. Flag if both CNI + mTOR inhibitor ordered with busulfan/TBI MA regimen. |
| Checkpoint Inhibitor Washout | Review prior therapy: PD-1/PD-L1 inhibitors or mogamulizumab within 8–12 weeks of planned conditioning start → escalated GVHD risk. Discuss with transplant team. |
| DLCO Hemoglobin Correction | Verify DLCO corrected for Hgb (Dinakara method). Uncorrected DLCO in anemic patient appears falsely low → may falsely contraindicate busulfan/carmustine. |
| Hydroxychloroquine | For cGVHD: 800 mg (12 mg/kg)/day. If used >2 years: annual ophthalmology for retinopathy. Highest doses used here are much higher than typical RA/lupus doses. |
| Ruxolitinib Dose Reduction | Hold if plt <50K or ANC <0.5K. Dose reduce to 5 mg BID if plt 50–100K. Monitor CBC biweekly in first month. JAK inhibitor immunosuppression → opportunistic infections. |
💎 CLINICAL PEARL: HCT TYPE SELECTION: Auto-HCT = cytotoxic benefit only (no GvL). Allo-HCT = GvL effect is potentially curative. Auto lower NRM but higher relapse. Allo higher NRM but lower relapse. Disease type + remission status determine which is appropriate.
💎 CLINICAL PEARL: BUSULFAN AUC TARGET: Underexposure = relapse. Overexposure = VOD/SOS + NRM. PK-guided dosing is superior to fixed-weight dosing (Anderson 2017). Optimal target undefined but most evidence supports 60–100 mg×h/L total AUC.
💎 CLINICAL PEARL: PTCy REVOLUTION: Post-transplant cyclophosphamide has made haploidentical HCT (50% HLA mismatch) feasible with outcomes comparable to MSD/MUD. It’s now the preferred prophylaxis backbone for haplo and MMUD transplants.
💎 CLINICAL PEARL: STEROID-REFRACTORY GVHD: Ruxolitinib is the ONLY FDA-approved Category 1 agent for BOTH SR-aGVHD AND SR-cGVHD. For cGVHD, ibrutinib, belumosudil, and axatilimab are additional FDA-approved options (Cat 2A). Always enroll in clinical trials first.
💎 CLINICAL PEARL: BELUMOSUDIL UNIQUENESS: Only agent with evidence for PULMONARY cGVHD response (lung ORR in ROCKstar). Unique ROCK2 kinase mechanism. For refractory BOS after ruxolitinib or ibrutinib failure.
💎 CLINICAL PEARL: VEDOLIZUMAB GI GVHD: Gut-selective mechanism (blocks α4β7 integrin → less T-cell trafficking to GI). Lower systemic immunosuppression than other 2nd-line agents → potentially fewer infections. Best used EARLY (2nd line) for steroid-refractory GI aGVHD.
💎 CLINICAL PEARL: CONDITIONING SELECTION RULE: MA → young, fit, aggressive disease (AML/ALL/MDS/CML). RIC → older, comorbid, lymphoma, CLL, plasma cell, prior auto-HCT. NMA → most fragile, indolent disease, complete reliance on GvL. HCT-CI >3 → lean toward RIC/NMA regardless of age.
💎 CLINICAL PEARL: CHIMERISM MATTERS: Declining donor chimerism post allo-HCT = early relapse signal. Complete donor chimerism (>95% in myeloid + lymphoid) = goal. Mixed chimerism may require IS taper